Fig. 3From: Deciphering tumor immune microenvironment differences between high-grade serous and endometrioid ovarian cancer to investigate their potential in indicating immunotherapy responseMutational signatures of HGSOC and EEOC patients. A, six different single nucleotide substitutions were detected in HGSOC and EEOC. B, proportions of somatic mutations in 17 mutation signatures for each patient. C, the contribution of signature 3 in HGSOC patients and EEOC patients. HGSOC, high-grade serous ovarian cancer. EEOC, endometrioid epithelial ovarian cancer. Data in C was shown as ‘Mean with SD’. Statistics in C: unpaired t testBack to article page